Department of Medical Microbiology, Faculty of Medicine, Giresun University, Giresun, Turkey.
Department of Medical Microbiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
J Mycol Med. 2017 Dec;27(4):506-513. doi: 10.1016/j.mycmed.2017.07.007. Epub 2017 Aug 24.
Meyerozyma (Pichia) guilliermondii exists in human skin and mucosal surface microflora. It can cause severe fungal infections like candidemia, which is an opportunistic pathogen. One hundred and forty-one M. guilliermondii isolates, consisting of 122 blood culture isolates, belonging to 126 patients; 13 total parenteral nutrition solution isolates; and two rectal swab isolates were identified according to carbohydrate assimilation reactions in a university hospital in Turkey between January 2006 and December 2015. Following Candida albicans (34.0%) and C. parapsilosis (21.2%), the third yeast species most commonly isolated from blood cultures in the Farabi Hospital was M. guilliermondii (20.6%). The patients were hospitalised in 27 different departments. A total of 50% of the patients were in pediatric departments, 49.2% were in intensive care units, and 17.2% were in haematology-oncology departments. Molecular identification of the isolates was performed using DNA sequence analysis of ribosomal ITS gene regions and IGS amplification-AluI fingerprinting (IGSAF). With molecular identification, 140 isolates were identified as M. guilliermondii and one isolate was identified as Candida membranifaciens. It was observed that the ITS1 region specifically helps in identifying these species. It was demonstrated that biochemical and molecular methods were 99.3% consistent in identifying M. guilliermondii. The Wild-Type (WT) Minimum Inhibitory Concentrations (MICs) distribution of fluconazole, voriconazole, itraconazole, and flucytosine were determined using the Sensititre YeastOne YO2V system after 24h of incubation. One M. guilliermondii strain was determined to be non-WT for fluconazole, voriconazole, itraconazole and flucytosine. In total, three M. guilliermondii strains, for fluconazole, were determined to be non-WT in this study.
梅里埃毕赤酵母（毕赤酵母）存在于人体皮肤和黏膜表面微生物群中。它可引起严重的真菌感染，如念珠菌血症，是一种机会性病原体。2006 年 1 月至 2015 年 12 月，在土耳其的一所大学医院，根据碳水化合物同化反应，鉴定了 141 株梅里埃毕赤酵母分离株，包括 122 株血培养分离株，属于 126 例患者；13 株全胃肠外营养溶液分离株；和 2 株直肠拭子分离株。在法拉比医院，从血培养中分离出的第三大酵母物种是白色念珠菌（34.0%）和近平滑念珠菌（21.2%），其次是梅里埃毕赤酵母（20.6%）。患者在 27 个不同的科室住院。50%的患者在儿科，49.2%在重症监护病房，17.2%在血液肿瘤科。使用核糖体 ITS 基因区域的 DNA 序列分析和 IGS 扩增-AluI 指纹（IGSAF）对分离物进行分子鉴定。通过分子鉴定，140 株被鉴定为梅里埃毕赤酵母，一株被鉴定为 Candida membranifaciens。结果表明，ITS1 区域特别有助于鉴定这些物种。结果表明，生化和分子方法在鉴定梅里埃毕赤酵母时具有 99.3%的一致性。使用 Sensititre YeastOne YO2V 系统，在孵育 24 小时后，测定氟康唑、伏立康唑、伊曲康唑和氟胞嘧啶的野生型（WT）最低抑菌浓度（MIC）分布。一株梅里埃毕赤酵母对氟康唑、伏立康唑、伊曲康唑和氟胞嘧啶的 WT 最小抑菌浓度（MIC）分布进行了测定。在这项研究中，总共确定了三株梅里埃毕赤酵母对氟康唑呈非 WT。
